Use of either Transcranial or Whole-Body Photobiomodulation Treatments improves COVID-19 Brain Fog.

R. Bowen,P. Arany

Published 2023 in Journal of Biophotonics

ABSTRACT

There is increasing recognition of post-COVID-19 sequelae involving chronic fatigue and brain fog for which Photobiomodulation (PBM) therapy has been utilized. This open-label, pilot, human clinical study examined the efficacy of two PBM devices - e.g., a helmet (1070 nm) for transcranial (tPBM); and a light bed (660 and 850 nm) for whole body (wbPBM) over a four-week period, with 12 treatments for two separate groups (n = 7 per group). Subjects were evaluated with a neuropsychological test battery including Montreal Cognitive Assessment (MoCA), digit symbol substitution test (DSST), trail-making tests A and B, physical reaction time (PRT); and a quantitative electroencephalography system (WAVi), Pre- and Post- the treatment series. Each device for PBM delivery was associated with significant improvements in cognitive tests (p < 0.05 and beyond). Changes in WAVi supported the findings. This study outlines the benefits of utilizing PBM therapy (transcranial or whole-body) to help treat long COVID brain fog. This article is protected by copyright. All rights reserved.

PUBLICATION RECORD

CITATION MAP

EXTRACTION MAP

CLAIMS

  • No claims are published for this paper.

CONCEPTS

  • No concepts are published for this paper.

REFERENCES

Showing 1-100 of 100 references · Page 1 of 1

CITED BY

Showing 1-19 of 19 citing papers · Page 1 of 1